Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of $164.99 billion. The enterprise value is $186.35 billion.
| Market Cap | 164.99B |
| Enterprise Value | 186.35B |
Important Dates
The last earnings date was Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | Sep 15, 2026 |
Share Statistics
Gilead Sciences has 1.24 billion shares outstanding. The number of shares has decreased by -1.39% in one year.
| Current Share Class | 1.24B |
| Shares Outstanding | 1.24B |
| Shares Change (YoY) | -1.39% |
| Shares Change (QoQ) | -0.88% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 87.26% |
| Float | 1.20B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 14.55 |
| PS Ratio | 5.42 |
| Forward PS | 5.24 |
| PB Ratio | 13.96 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.75 |
| P/OCF Ratio | 12.17 |
| PEG Ratio | 2.34 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 708.56, with an EV/FCF ratio of 14.40.
| EV / Earnings | n/a |
| EV / Sales | 6.12 |
| EV / EBITDA | 708.56 |
| EV / EBIT | n/a |
| EV / FCF | 14.40 |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 2.23.
| Current Ratio | 1.27 |
| Quick Ratio | 0.90 |
| Debt / Equity | 2.23 |
| Debt / EBITDA | 99.79 |
| Debt / FCF | 2.03 |
| Interest Coverage | -2.50 |
Financial Efficiency
Return on equity (ROE) is -20.68% and return on invested capital (ROIC) is 34.37%.
| Return on Equity (ROE) | -20.68% |
| Return on Assets (ROA) | 14.09% |
| Return on Invested Capital (ROIC) | 34.37% |
| Return on Capital Employed (ROCE) | -6.51% |
| Weighted Average Cost of Capital (WACC) | 5.67% |
| Revenue Per Employee | $1.79M |
| Profits Per Employee | -$190,588 |
| Employee Count | 17,000 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 3.29 |
Taxes
In the past 12 months, Gilead Sciences has paid $1.29 billion in taxes.
| Income Tax | 1.29B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.43% in the last 52 weeks. The beta is 0.34, so Gilead Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +11.43% |
| 50-Day Moving Average | 129.66 |
| 200-Day Moving Average | 132.12 |
| Relative Strength Index (RSI) | 53.15 |
| Average Volume (20 Days) | 6,923,734 |
Short Selling Information
The latest short interest is 25.26 million, so 2.04% of the outstanding shares have been sold short.
| Short Interest | 25.26M |
| Short Previous Month | 25.48M |
| Short % of Shares Out | 2.04% |
| Short % of Float | 2.10% |
| Short Ratio (days to cover) | 3.06 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of $30.46 billion and -$3.24 billion in losses. Loss per share was -$2.61.
| Revenue | 30.46B |
| Gross Profit | 24.25B |
| Operating Income | 11.84B |
| Pretax Income | -1.96B |
| Net Income | -3.24B |
| EBITDA | 263.00M |
| EBIT | -2.50B |
| Loss Per Share | -$2.61 |
Balance Sheet
The company has $4.88 billion in cash and $26.25 billion in debt, with a net cash position of -$21.36 billion or -$17.23 per share.
| Cash & Cash Equivalents | 4.88B |
| Total Debt | 26.25B |
| Net Cash | -21.36B |
| Net Cash Per Share | -$17.23 |
| Equity (Book Value) | 11.75B |
| Book Value Per Share | 9.53 |
| Working Capital | 2.93B |
Cash Flow
In the last 12 months, operating cash flow was $13.55 billion and capital expenditures -$609.00 million, giving a free cash flow of $12.94 billion.
| Operating Cash Flow | 13.55B |
| Capital Expenditures | -609.00M |
| Depreciation & Amortization | 2.76B |
| Net Borrowing | 1.29B |
| Free Cash Flow | 12.94B |
| FCF Per Share | $10.44 |
Margins
Gross margin is 79.60%, with operating and profit margins of 38.88% and -10.64%.
| Gross Margin | 79.60% |
| Operating Margin | 38.88% |
| Pretax Margin | -6.42% |
| Profit Margin | -10.64% |
| EBITDA Margin | 0.86% |
| EBIT Margin | -8.20% |
| FCF Margin | 42.50% |
Dividends & Yields
This stock pays an annual dividend of $3.28, which amounts to a dividend yield of 2.47%.
| Dividend Per Share | $3.28 |
| Dividend Yield | 2.47% |
| Dividend Growth (YoY) | 3.50% |
| Years of Dividend Growth | 10 |
| Payout Ratio | n/a |
| Buyback Yield | 1.39% |
| Shareholder Yield | 3.85% |
| Earnings Yield | -1.96% |
| FCF Yield | 7.84% |
Analyst Forecast
The average price target for Gilead Sciences is $157.41, which is 18.30% higher than the current price. The consensus rating is "Buy".
| Price Target | $157.41 |
| Price Target Difference | 18.30% |
| Analyst Consensus | Buy |
| Analyst Count | 29 |
| Revenue Growth Forecast (3Y) | 5.25% |
| EPS Growth Forecast (3Y) | 9.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Gilead Sciences has an Altman Z-Score of 4.05 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.05 |
| Piotroski F-Score | 5 |